Abstract
A prospective study with two cytotoxic combinations (cyclophosphamide, methotrexate, and fluorouracil (CMF), and adriamycin plus vincristine (AV)) was carried out in 110 patients with advanced breast cancer. There was no significant difference between the treatment groups in the response rate after primary treatment, the median duration of response, and the median survival. In both groups responders survived for longer than non-responders. Secondary treatment after crossover for progression or relapse resulted in response rates of 35% for AV and 20% for CMF. Toxicity was mainly represented by reversible haemosuppression. These results are comparable with those obtained with other multiple-drug regimens, and combination chemotherapy alone seems to have reached a plateau in its capacity to control disseminated breast cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- De Lena M., Brambilla C., Morabito A., Bonadonna G. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer. 1975 Apr;35(4):1108–1115. doi: 10.1002/1097-0142(197504)35:4<1108::aid-cncr2820350414>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
- Jones S. E., Durie B. G., Salmon S. E. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer. 1975 Jul;36(1):90–97. doi: 10.1002/1097-0142(197507)36:1<90::aid-cncr2820360104>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
- Mantel N. Ranking procedures for arbitrarily restricted observation. Biometrics. 1967 Mar;23(1):65–78. [PubMed] [Google Scholar]